Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer Intervention:   Drug: Nivolumab Sponsors:   Seoul National University Hospital;   Seoul National University Bundang Hospital;   Korean Cancer Study Group (KCSG);   Eisai Korea;   Ono pharmaceutical Korea Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

The trial examined HER2-positive breast cancer in patients with tumors smaller than 1cm; it is one of only a few to assess treatments in tumors this small.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Though current pathological methods are greatly improved, they provide rather limited functional information. Cell-in-cell structures (CICs), arising from active cell–cell interaction, are functional surrogates of complicated cell behaviors within heterogeneous cancers. In light of this, we performed the subtype-based CIC profiling in human breast cancers by the “EML” multiplex staining method, and accessed their values as prognostic factors by Cox univariate, multivariate, and nomogram analysis. CICs were detected in cancer specimens but not in normal breast tissues. A total of five types of CICs were id...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Metastatic Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: SHR6390;   Drug: Letrozole;   Drug: Capecitabine Sponsors:   Jinming Yu;   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Positive Breast Cancer Intervention:   Drug: TCHP Sponsor:   Guangdong General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: SHR6390;   Drug: Letrozole;   Drug: Capecitabine Sponsors:   Jinming Yu;   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Positive Breast Cancer Intervention:   Drug: TCHP Sponsor:   Guangdong General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ist S, Paluchoswski P, Wilke C, Heilenkötter U, Terracciano L, Müller V, Wilczak W, Burandt EC Abstract Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression in 2,197 breast cancers. LPCAT1 staining was found in 97.8% of 1,774 interpretable tumors, including 48.1% with weak, 28.7% with moderate, and 14.4% with strong expression. The frequency of LPCAT1 positivity depended on the histological tumor type. Moderate or strong LPCAT1 positivity was more com...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Publication date: Available online 16 September 2019Source: Pathology - Research and PracticeAuthor(s): Yu-Hui Zhou, Yang Liu, Wei Zhang, Chao Liu, Jian-Jun He, Xiao-Jiang TangABSTRACTBackgroundChemotherapy is the predominant treatment option for patients with breast cancer. Selection of patients according to biomarker will improve chemotherapy efficacy. In the present study, we examined the relations of the expression of candidate genes and 21-recurrence score (RS) results to patients’ demographic characteristics, histopathological factors, and outcomes.MethodsA total of 146 patients were enrolled in this study. The...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
A causal link between Human Papillomavirus (HPV) and breast cancer (BC) remains controversial. In spite of this, the observation that HPV DNA is over-represented in the Triple Negative (TN) BC has been reported. Here we remark the high prevalence of HPV DNA (44.4%) in aggressive BC subtypes (TN and HER2+) in a population of 273 Italian women and we convey the presence of HPV DNA in the epithelial and stromal compartments by in situ hybridization. As previously reported, we also found that serum derived-extracellular vesicles (EVs) from BC affected patients contain HPV DNA. Interestingly, in one TNBC patient, the same HPV D...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Breast Carcinoma Metastatic in the Bone;   HER2/Neu Negative;   Metastatic Breast Carcinoma;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8 Interventions:   Drug: Paclitaxel;   Radiation: Radium Ra 223 Dichloride Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hospitals | Research